Proactive One2One Virtual Investor Forum

RNS Number : 8144U
Arix Bioscience Plc
08 April 2021
 

Arix Bioscience PLC
Arix to Present at the Proactive One2One Virtual Investor Forum

08-Apr-2021

 

 

Arix Bioscience plc

 

Arix to Present at the Proactive One2One Virtual Investor Forum

 

LONDON, 08 April 2021: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, announces that Naseem Amin, Executive Chairman, will present at the Proactive One2One Virtual Investor Forum today, Thursday, 8 April 2021 at 7:00pm BST. Arix will be one of four companies presenting on the evening, each having a presentation slot followed by Q&A, with the webinar taking place from 6.00pm.

Investors can register to attend here:   https://event.webinarjam.com/register/1024/gwwg2hxq9

A replay of the presentation will be available after the event, on the investor relations section of the Arix website at  https://arixbioscience.com/investor-relations/events-presentations

[ENDS]

For more information on Arix, please contact:

 

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

 

 

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

 

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 

 

 

 

Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAXLPEENFEEA
UK 100

Latest directors dealings